CN104302311A - 成纤维细胞生长因子21蛋白质的治疗用途 - Google Patents

成纤维细胞生长因子21蛋白质的治疗用途 Download PDF

Info

Publication number
CN104302311A
CN104302311A CN201380025338.6A CN201380025338A CN104302311A CN 104302311 A CN104302311 A CN 104302311A CN 201380025338 A CN201380025338 A CN 201380025338A CN 104302311 A CN104302311 A CN 104302311A
Authority
CN
China
Prior art keywords
seq
bone
fgf21 protein
fgf21
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380025338.6A
Other languages
English (en)
Chinese (zh)
Inventor
Y·L·马
A·R·伊里萨里罗维拉
V·L·雷诺兹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104302311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104302311A publication Critical patent/CN104302311A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380025338.6A 2012-05-15 2013-05-09 成纤维细胞生长因子21蛋白质的治疗用途 Pending CN104302311A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261646974P 2012-05-15 2012-05-15
US61/646,974 2012-05-15
US201361786939P 2013-03-15 2013-03-15
US61/786,939 2013-03-15
PCT/US2013/040275 WO2013173158A1 (en) 2012-05-15 2013-05-09 Therapeutic uses of fibroblast growth factor 21 proteins

Publications (1)

Publication Number Publication Date
CN104302311A true CN104302311A (zh) 2015-01-21

Family

ID=48483225

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380025338.6A Pending CN104302311A (zh) 2012-05-15 2013-05-09 成纤维细胞生长因子21蛋白质的治疗用途

Country Status (21)

Country Link
US (1) US20150141335A1 (enExample)
EP (1) EP2852398A1 (enExample)
JP (1) JP2015522539A (enExample)
KR (1) KR20150002801A (enExample)
CN (1) CN104302311A (enExample)
AU (1) AU2013263188A1 (enExample)
BR (1) BR112014028413A2 (enExample)
CA (1) CA2869320A1 (enExample)
CL (1) CL2014002846A1 (enExample)
CO (1) CO7131381A2 (enExample)
EA (1) EA201491856A1 (enExample)
HK (1) HK1202800A1 (enExample)
IL (1) IL235482A0 (enExample)
MA (1) MA37506B1 (enExample)
MX (1) MX2014013913A (enExample)
PE (1) PE20142432A1 (enExample)
PH (1) PH12014502537A1 (enExample)
SG (1) SG11201407655TA (enExample)
TN (1) TN2014000409A1 (enExample)
WO (1) WO2013173158A1 (enExample)
ZA (1) ZA201407532B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108324928A (zh) * 2018-03-05 2018-07-27 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2726511B1 (en) 2011-07-01 2019-08-07 NGM Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2925775B1 (en) 2012-11-28 2020-09-16 NGM Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
KR102724421B1 (ko) 2012-12-27 2024-10-30 엔지엠 바이오파마슈티컬스, 아이엔씨. 담즙산 항상성의 조절 및 담즙산 질환 및 질병의 치료 방법
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
KR102178945B1 (ko) 2013-10-28 2020-11-13 엔지엠 바이오파마슈티컬스, 아이엔씨. 암 모델 및 관련 방법
SI3097122T1 (sl) 2014-01-24 2020-07-31 Ngm Biopharmaceuticals, Inc. Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
CA2951153A1 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (ja) * 2014-09-08 2018-04-11 国立大学法人大阪大学 脱髄疾患の予防又は治療剤
CN107108711B (zh) 2014-10-23 2021-11-23 恩格姆生物制药公司 包含肽变异体的药物组合物及其使用方法
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
JP6728352B2 (ja) 2015-11-09 2020-07-22 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 胆汁酸に関係した障害の治療方法
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
WO2023284822A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906530A (zh) * 2011-10-04 2014-07-02 伊莱利利公司 成纤维细胞生长因子21变体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068909B1 (en) * 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103906530A (zh) * 2011-10-04 2014-07-02 伊莱利利公司 成纤维细胞生长因子21变体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FAZELI ET AL: "SerumFGF-21 levels are associated with worsened radial trabecular bone microarchitecture and decreased radial bone strength in women with anorexia nervosa", 《BONE》 *
LEE ET AL.: "Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?", 《OSTEOPOROS INT》 *
LI ET AL.: "fibroblast grow factor 21 concentration in serum and synovial fluid is associated with radiographic bone loss of knee osteoarthritis", 《SCAND J CLIN LAB INVEST》 *
WEI WEI ET AL.: "fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome profliferator-activated receptor gamma", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA》, 29 February 2012 (2012-02-29), pages 3143 - 3148, XP002712351, DOI: 10.1073/pnas.1200797109 *
WU ET AL: "Fibroblast Growth Factor 21 (FGF21) Inhibits Chondrocyte Functio", 《J BIOL CHEM》 *
ZHANG ET AL.: "The starvation hormone, fibroblastgrowth factor-21, extends lifespan in mice Yuan Zhang et al", 《ELIFE》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108324928A (zh) * 2018-03-05 2018-07-27 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用
CN108324928B (zh) * 2018-03-05 2020-09-08 哈尔滨医科大学 重组人成纤维细胞生长因子-5在促骨折愈合中的应用

Also Published As

Publication number Publication date
HK1202800A1 (en) 2015-10-09
BR112014028413A2 (pt) 2017-11-07
PH12014502537A1 (en) 2015-01-21
CL2014002846A1 (es) 2015-01-30
PE20142432A1 (es) 2015-01-22
JP2015522539A (ja) 2015-08-06
IL235482A0 (en) 2014-12-31
CO7131381A2 (es) 2014-12-01
EA201491856A1 (ru) 2015-03-31
CA2869320A1 (en) 2013-11-21
WO2013173158A1 (en) 2013-11-21
ZA201407532B (en) 2016-05-25
MA37506B1 (fr) 2017-03-31
KR20150002801A (ko) 2015-01-07
US20150141335A1 (en) 2015-05-21
MA37506A1 (fr) 2016-01-29
AU2013263188A1 (en) 2014-10-16
SG11201407655TA (en) 2014-12-30
EP2852398A1 (en) 2015-04-01
TN2014000409A1 (en) 2015-12-21
MX2014013913A (es) 2015-02-17

Similar Documents

Publication Publication Date Title
CN104302311A (zh) 成纤维细胞生长因子21蛋白质的治疗用途
Drake et al. Cathepsin K inhibitors for osteoporosis: biology, potential clinical utility, and lessons learned
Varela et al. One year of abaloparatide, a selective activator of the PTH1 receptor, increased bone formation and bone mass in osteopenic ovariectomized rats without increasing bone resorption
Foldynova‐Trantirkova et al. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias
Siddiqui et al. Physiological bone remodeling: systemic regulation and growth factor involvement
Delmas Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases
Lozano et al. Role of parathyroid hormone-related protein in the decreased osteoblast function in diabetes-related osteopenia
Ominsky et al. Sustained modeling‐based bone formation during adulthood in cynomolgus monkeys may contribute to continuous BMD gains with denosumab
Henriksen et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
Takyar et al. EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone
Ansari et al. Autocrine and paracrine regulation of the murine skeleton by osteocyte‐derived parathyroid hormone‐related protein
Clowes et al. Potential role of pancreatic and enteric hormones in regulating bone turnover
Sabir et al. The evolving therapeutic landscape of genetic skeletal disorders
US20150352131A1 (en) Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis
EA016041B1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
Robling et al. Anabolic and catabolic regimens of human parathyroid hormone 1–34 elicit bone-and envelope-specific attenuation of skeletal effects in Sost-deficient mice
Lozano et al. The C‐terminal fragment of parathyroid hormone‐related peptide promotes bone formation in diabetic mice with low‐turnover osteopaenia
Appelman-Dijkstra et al. Novel approaches to the treatment of osteoporosis
US20030109537A1 (en) Methods and materials for treating bone conditions
Yavropoulou et al. Incretins and bone: evolving concepts in nutrient-dependent regulation of bone turnover
Luo et al. Progesterone upregulates TGF-b isoforms (b1, b2, and b3) expression in normal human osteoblast-like cells
Noda et al. Osteopontin
Mentaverri et al. Potential anti-catabolic and anabolic properties of strontium ranelate
Yuan et al. Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
WO2015057836A2 (en) Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150121